NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.355) was uploaded to the NHS England Website on Thursday 20, March 2025.
The following changes have been introduced:
Futibatinib (FUT1)
For the treatment of patients for locally advanced or metastatic cholangiocarcinoma which has a fibroblast growth factor receptor 2 gene fusion/rearrangement in patients with disease progression during or after previous systemic therapy where the following criteria have been met
Treatment criteria added
Durvalumab in combination with etoposide plus either carboplatin or cisplatin (DUR4)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Pemigatinib (PEMIG1)
For locally advanced or metastatic cholangiocarcinoma which has a fibroblast growth factor receptor 2 gene fusion/rearrangement in patients with disease progression during or after previous systemic therapy where the following criteria have been met
Treatment criteria (#6 and 13) updated